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Extracellularproteolysis isassociated with cell migration andtissue remodelling
(1). In particular, plasminogen activators (PAs)' are produced by mono-
cytes/macrophages involved in inflammatory reactions (2, 3). In the context of
the focalcontrol ofPA-mediated extracellular proteolysis, the cellular production
of specific protease inhibitors and its possible hormonal control are thus of
particular interest.
The existence of protease inhibitors with a high affinity for PAs has been
demonstrated in several tissues and cultured cell types. An inhibitor of the
urokinase-type PA (uPA), first identified in human placenta by Kawano et al.
(4), has been purified (5) (T. C. Wun and E. Reich, manuscript in preparation).
This PA-specific inhibitor (PAI), named PAI-2, forms SDS-resistant, presumably
covalent, complexes with uPA and tissue-type PA (WA), and such complexes lack
enzymatic activity; PAI-2 has a very high affinity for PAs (6) and does not react
with plasmin or thrombin. Human fibroblasts have also been shown to secrete a
variety of protease ligands, named protease-nexins (PN) (7, 8). The protease-PN
complexes bind to fibroblasts through their PN moiety, and are rapidly inter-
nalized and degraded (9). PN1, which has been purified (10, 11), can be clearly
distinguished from PAI-2 by pI and by its reactivity towards other serine
proteases, such as thrombin and plasmin. Another PAI, named PAI-I, produced
by bovine endothelial cells (12, 13) and present in human platelets (14), has also
been characterized. The unusual stability of this PAI to acid or SDS is in contrast
to the lability of the other protease inhibitors discussed above.
Until recently, no specific PAI had been identified in plasma, and the generally
accepted view was that the already known plasma protease inhibitors were solely
responsible for the inactivation of PAs in plasma (15, 16). The existence of fast-
acting PAI(s) in plasma has now been conclusively demonstrated (17-19); some
ofthese areantigenically related to the PAI-2 (20), and others to the PAI-1 (21).
Mononuclearphagocytesalso secrete fibrinolytic inhibitors (22, 23), and recent
studies (24-28) have established some ofthe characteristics of PA-specific ligands
secreted by monocytes/macrophages. In view of the importance of controlled
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extracellular proteolysis in inflammatory reactions, a detailed understanding of
the characteristics of the PAI(s) produced by mononuclear phagocytes is of
obvious interest . We have previously shown that cells from the human histiocytic
lymphoma-derived U 937 line, as well as monocytes purified from human
peripheral blood, simultaneously secrete the single-chain zymogen pro-uPA and
an inhibitor of active two-chain uPA (25). We provide here an analysis of the
biochemical properties of the monocyte and U 937-produced PAIs. In particular
we show that monocytes/macrophages synthesize two functionally and antigeni-
cally related forms of PAL a predominantly intracellular protein, corresponding
to that described in our previous work (25), and a glycosylated, preferentially
secreted form. The production of these PAIs is enhanced under conditions that
promote the differentiation of mononuclear phagocytes (29) and modulate their
functional activity (30).
Materials and Methods
Materials.
￿
Purified human tPA from HeLa cells, and rabbit antibody to human uPA
were the kind gift of Dr. W. D. Schleuning. Affinity-purified rabbit IgG raised against
PAI-2 from human placenta was kindly provided by Dr. T. C. Wun; rabbit antiserum to
PAI-1 from bovine aortic endothelial cells was the generous gift of Dr. D. J. Loskutoff;
rabbit antiserum to the purified low-M, PAI from U 937 cells was the kind gift of Dr. E.
K. O. Kruithof. 125I-labeled plasma kallikrein and factor X11f (106 cpm/ug) were kindly
provided by Dr. A. de Agostini. Mr 55,000 uPA (1 .5 x 105 U/mg) was from the Green
Cross Corporation (Osaka, Japan); M, 33,000 uPA was generously provided by Serono
(Denens, Switzerland). Actinomycin D (A-4262), cycloheximide (C-6255), Clostridium
perfringens neuraminidase (N-2133), NP-40 (N-6507), phorbol 12-myristate 13-acetate
(PMA) (P-8139), porcine pancreatic trypsin (T-0134), thrombin from human plasma (T-
6759), tunicamycin (T-7765), and soybean trypsin inhibitor (T-9003) were from Sigma
Chemical Co. (St Louis, MO). Trasylol was obtained from Bayer (Zurich, Switzerland).
Porcine pancreatic elastase was obtained from Elastin Products Co. (Pacific, MI). Bovine
serum albumin (BSA) was obtained from Miles (Rehovot, Israel); stock solutions were
acid-treated before use. Sephadex G-50 and G-200, Concanavalin A-Sepharose, carrier
ampholytes (Pharmalytes; pH 3-10 and 4-6.5), Percoll, and low-M, electrophoresis
calibration kit were from Pharmacia Fine Chemicals (Uppsala, Sweden), Ultrogel ACA
54 from LKB Instruments Inc. (Bromma, Sweden), Streptococcus aureus (Pansorbin) from
Calbiochem Behring (La Jolla, CA) and methyl-a-D-mannopyranoside from Fluka Chem-
ical Co. (Bucks, Switzerland). Na['251],L-["S]methionine, and En'Hance were obtained
from Amersham Corp. (Amersham,Great Britain). RPMI 1640 and FCS were from Gibco
Laboratories, (Grand Island, NY), Triton X-100 from Merck and Co., Inc. (Rahway, NJ),
SDS from Bio-Rad Laboratories (Richmond, CA), Iodogen from Pierce Chemical Co.
(Rockford, IL), and acrylamide, bisacrylamide, N,N,N',N'-tetramethylethylenediamine
and ammonium persulfate from Eastman Kodak Co. (Rochester, NY). All the other
chemicals were of the best commercial grade available. Tissue culture plasticware was
from Falcon Labware (Oxnard, CA). Plasminogen was purified from human plasma (31).
Cell Culture.
￿
Cultures of U 937 cells and human peripheral blood monocytes, and
preparation of conditioned media were performed as previously described (25); incuba-
tions were performed in RPMI 1640 + 1 mg/ml BSA . Cells were collected by centrifuga-
tion (10 min at 300 g), washed three times with PBS + 1 mg/ml BSA, and lysed in 0.2%
Triton X-100, 0.1 M Tris HCI, pH 8 .1 . Nuclei and cell debris were removed by
centrifugation for 10 min at 750 g, and the cell extracts stored at -20°C.
Trypsin Treatment.
￿
To investigate the accessibility of the cell-associated low-Mr PAI to
trypsin, U 937 cells were collected, washed twice in serum-free RPMI 1640, and resus-
pended at 106 cells/ml in RPMI 1640 + I mg/ml BSA. Alternatively, the cells were lysed
at the same density in PBS + 0.2% Triton X-100, and the nuclei were discarded by322
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centrifugation for 10 min at 1,000 g. Intact and lysed cells were further processed in
parallel. Trypsin was added to the samples at a final concentration of 5 ug/ml, and the
cells were incubated for various times at 37°C . Proteolysis was blocked by cooling the
samples on ice and by the concomitant addition of soybean trypsin inhibitor at a final
concentration of 50 jug/ml. Intact trypsin-treated cells were subsequently lysed as described
above.
1251 Labeling ofu-PA, Thrombin, Trypsin, and Elastase.
￿
The proteins were labeled with
Iodogen as previously described (25); the specific activities of the 1251-enzymes were as
follows: A 55,000 uPA, 1-2 X 10' cpm/tug; M, 33,000 uPA, 0.8-1 .7 X 10' cpm/kg;
thrombin, 3 X 106 cpm/,ug (two radioactive peptides were present in the preparation of
1251-thrombin; one unidentified contaminant of M, 20,000, and thrombin itself, at Mr
34,000; trypsin, 3.4 X 106 cpm/,ug; elastase, 7 X 106 cpm/ug. Plasminogen (6-7 X 106
cpm/Ag) was converted to 1251-plasmin by incubation at 30°C for 18 h in presence of 100
U/ml uPA and 50% glycerol; the extent of conversion of 1251-labeled one-chain plasmin-
ogen into two-chain plasmin was determined by SDS-PAGE under reducing conditions
and autoradiography.
Formation of Enzymellnhibitor Complexes.
￿
Unless specifically indicated, 5 'I of
1251_
enzyme (0.5-2 ng) were added to 10 u1 of the samples to be tested; after I h at VC, C, the
reaction was stopped by adding an equal volume ofdouble-strength electrophoresis sample
buffer. For competition studies, the samples were preincubated for 30 min at 4 °C with a
20-100-fold excess unlabeled enzyme before their incubation with 1251-enzyme.
Like the other inhibitors of the serpin family (32), U 937-produced PAIs complex uPA
essentially irreversibly. Therefore, the sensitivity of uPA to the PAIs cannot be measured
by K;. Formation of nondissociating protease/inhibitor complexes can be kinetically
resolved into two steps: (a) initial formation of a reversible complex that dissociates at a
finite rate,and (b) conversion of the reversible complex into a stable complex. At protease
and inhibitor concentrations below the micromolar range, the reactions proceed according
to simple second-order kinetics. The corresponding association constants (ka-) have been
used to compare the specificity of a-I proteinase inhibitor (33) and that of protease nexin
(11) for different proteases. In the case of the U 937-produced PAls, the plots of 1/V
versus time (calculated from the data illustrated in Fig. 4) were linear up to 10 min; this
was consistent with simple, second-order kinetics, and has allowed us to determine the
ka,,_ of uPA with the U 937-produced PAIs.
SDS-PAGE.
￿
SDS-PAGE and processing of the electrophoretic gels for autoradiography
were performed as previously described (25). Molecular weight standards were run on
the same gels, and their positions are indicated on the margin; the A values of the
different species present were calculated from the positions of the markers.
Biosynthetic Labeling.
￿
U 937 cells were collected by centrifugation, washed three times
in PBS + I mg/ml BSA, and resuspended at 2 X 106 cells/ml in a modified culture
medium containing 80,uCi/ml [15S]methionine, 90% methionine-free DMEM, 10% RPMI
1640, 1 mg/ml BSA, and, when indicated, 30 ng/ml PMA. After 24 h at 37°C, the
conditioned media were collected by centrifugation. The cells were washed once with
PBS, centrifuged, and resuspended in 0 .6% Triton X-100, 0.1 M Tris HCI, pH 8.1, and
200 KIU/ml Trasylol ; Triton X-100 and Trasylol were also added to the conditioned
media to obtain the same final concentrations as in the cell extracts. Aliquots of the "S-
labeled conditioned media or cell extracts were incubated for 1 h at 4°C with M, 33,000
unlabeled uPA (1 .5 wg/ml) or an equal volume of PBS. The samples were then incubated
for 30 min at 20'C with S. aureus, centrifuged, and the pellets discarded. The supernatants
were then immunoprecipitated with anti-uPA IgG (36 ttg/ml) or nonimmune IgG (40
tug/ml) (see below); the supernatants and pellets of immunoprecipitation were subjected
to SDS-PAGE. The gels were fixed, stained, treated with En"Hance before drying, and
exposed to Kodak SB-5 films at -80°C.
Immunoprecipitation.
￿
This was performed as previously described (25) with the follow-
ing modifications: the samples were first incubated with A 33,000
1211_UPA; 15 j1 aliquots
were subsequently mixed with 2 jl of anti-uPA IgG (0.5 mg/ml), anti-placental PAI-2
IgG (0.6 mg/ml), antiserum to endothelial PAI-I (1 :5 dilution), or nonimmune IgG (1 .2WOHLWEND ET AL.
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mg/ml). After 2 h at VC, C, S. aureus (15 ,u1) were added, the samples were further incubated
for 30 min at 20 ° C, and the suspensions were centrifuged (5 min; Beckman microfuge).
The supernatants were mixed with an equal volume of double-strength electrophoresis
sample buffer, containing 5% 2-ME. The pellets were washed three times with NET-TS
(0.5 M NaCl, 1 mM EDTA, 50 mM Tris HCI, pH 8.1 ; 1% Triton X-100, 0.2% SDS),
once with NET-TU (as NET-TS, expected that SDS is replaced by 1 M urea), and once
with NT-S (0.5 M NaCl, 50 mM Tris HCI, pH 8 .1 ; 0.1 % SDS), and finally eluted with 30
A1 of sample buffer + 5% 2-ME. Both supernatants and immunoprecipitates were heated
5 min at 100'C before SDS-PAGE, and the gel was processed for autoradiography.
Gel Filtration.
￿
Ultrogel ACA 54 was equilibrated in 0.2 M ammonium acetate, pH
7.0. Conditioned media (5-10 ml) were lyophilized, resuspended in 0.5-1 ml 0.2 M
ammonium acetate, pH 7 .0, applied to the column, and 2 ml fractions were collected.
Aliquots of the fractions were subsequently incubated with M, 33,000 1251-uPA and
analyzed by SDS-PAGE and autoradiography.
Concanavalin A-Sepharose.
￿
Conditioned media (0.4-0 .6 ml) were loaded on a Con A-
Sepharose column (I ml), previously equilibrated in PBS. The column was washed with
PBS and eluted with 0.2 M methyl-a-D-mannopyranoside in PBS + I mg/ml BSA. Aliquots
of the fractions collected were subsequently incubated with M, 33,000 1251-uPA and
analyzed by SDS-PAGE and autoradiography.
Analytical Isoelectric Focusing.
￿
Conditioned media (1 ml) were lyophilized, resuspended
in 0.1 ml water, and applied to spun Sephadex G-50 columns (34) equilibrated in carrier
ampholytes (pH 3-10 or pH 4-6.5). The samples were then subjected to IEF in Sephadex
G-200 previously equilibrated in the corresponding ampholytes, as described in the
instruction manual (Pharmacia Fine Chemicals). Alternatively, the samples were incubated
for 1 h at 37 ° C in presence of 0.1 U/ml neuraminidase before IEF. The gels were
subsequently fractionated and the fractions were reconstituted in 0.25 ml water. The pH
of the fractions was measured and subsequently brought back to neutrality by addition of
0.1 ml I M Tris HCI, pH 7.4. The samples were further incubated with M, 33,000 1251-
uPA and analyzed by SDS-PAGE and autoradiography.
Results
Synthesis and Secretion ofPAIs by U937 Cells in Response to PMA.
￿
To investigate
a possible modulation of production of the PAI we had previously identified
(25), U 937 cells were cultured in presence of PMA. Conditioned media were
collected at different times, and incubated with M, 33,000 ' 251-uPA. The pres-
ence of PAIs was detected by the formation of radiolabeled enzyme/ligand
complexes; these complexes were stable in SIDS-PAGE, and could be visualized
by autoradiography as radioactive bands of slower electrophoretic mobility than
the free enzyme. An increase in release of a ligand forming an M,. 72,000
complex with 1251-uPA was observed after 6 h of incubation in presence of PMA.
A ligand forming a M,. 94,000 complex with M,. 33,000 1251-uPA was detected in
the medium after 9 h (Fig. 1 A); upon longer incubation (24 h), the conditioned
medium of PMA-treated U 937 cells contained mainly the ligand forming the
higher-M,, complex (Fig. 1 A). Both ligands were found to be inhibitors of uPA:
as previously shown for the M, 72,000 complex (25), zymographic analysis
revealed that the specific catalytic activity of theMr 94,000 complex was markedly
lower than that of free uPA (data not shown). These ligands will thus be referred
to as low-M,- and high-M,. PAIs, respectively. The induced secretion of the high-
M, PAI was detectable down to a concentration of 1 ng/ml of PMA.
The amount of PAI present in conditioned media and cell extracts of control
and PMA-treated U 937 cells was determined; the values from a representative
experiment are presented in Table I .324
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FIGURE 1 .
￿
Production of PAIs by U 937 cells in response to PMA. (A) Time course. U 937
cells were resuspended at 2 X 106 cells/ml in RPMI + I mg/ml BSA alone (lanes 2, 4, 6, 8,
and 10) or containing 10 ng/mlPMA (lanes 3, 5, 7, 9, and 11), and incubated for 1 h (lanes 2
and 3), 3 h (lanes 4 and 5), 6 h (lanes 6 and 7), 9 h (lanes 8and 9), or 24 h (lanes 10 and 11) ;
control : culture medium without cells (lane 1) . Samples (10 Al) of control and conditioned
media were incubated for 1 h at 4 °C with ' 251-uPA (2 ng), and analyzed by SDS-PAGE and
autoradiography . M, were calculated from the positions of markers in the stained gel . (B)
Effects of actinomycin Dand cycloheximide. U 937 cells (2 X 106 cells/ml) were incubated for
16 h in RPMI + I mg/ml BSA with or without 10 ng/ml PMA, 5 jAg/ml actinomycin D, and
5 jug/ml cycloheximide, as indicated . The conditioned media were then processed as described
in A .
Culture
TABLE I
Quantitation ofPAI in U 937 Cultures
[PAI]*
(micrograms per 2 X 106 cells per 20 h)
Conditioned
￿
Cell extract medium
Control
￿
0 .03
￿
1 .29
PMA-treated
￿
1 .31
￿
1 .48
* The M, 72,000 and 94,000 radiolabeled complexes formed upon incu-
bation with 1251-uPAwere quantitated by cutting the appropriate regions
ofthe electrophoretic gels andcounting their radioactivity .Theamount
of PAIwas calculated on the basis of the specific activity of 1251-uPA and
of the stoichiometry of the complexes (Fig . 5); this calculation takes into
account the fact that the conditioned medium of PMA-treated cells
contained mainly the high-M, PALand that the other samples contained
only the low-M, PAL
To investigate the mechanism of PMA-mediated induction of PAI secretion,
we incubated U 937 cells with PMA in presence of drugs that interfere with
RNA or protein synthesis, i.e ., actinomycin D and cycloheximide, respectively
(Fig . I B) . The secretion of the high-Mr PAI was dependent upon ongoingRNA
and protein synthesis, in contrast to the release of the low-M, PAI, which
appeared unaffected by these drugs .
To determine whether PMA enhanced the synthesis of these PAIs,U 937 cells
were incubated in presence of [35S]methionine . The biosynthetically labeled
conditioned media and cell extracts of control and PMA-treated cultures were
incubated with M, 33,000 unlabeled urokinase, and the uPA/35S-labeled-PAIWOHLWEND ET AL .
￿
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FIGURE 2 .
￿
Immunoprecipitation of [ssS]methionine-labeled PAIs produced by U 937 cells:
effects ofPMA. U 937 cells were biosynthetically labeled with [
s5S]methionine, in absence (A)
or in presence (B) of 30 ng/ml PMA. Cell extracts (lanes 1-4) and conditioned media (lanes
5-8) were collected after 24 h of culture, and incubated with M, 33,000 unlabeled uPA (1 .5
jig/ml) (lanes 3, 4, 7, and 8) or an equal volume of PBS (lanes 1, 2, 5, and 6), before
immunoprecipitation with anti-uPA IgG (lanes 1, 3, 5, and 7) or nonimmune IgG (lanes 2, 4,
6, and 8) . For comparison, M, 33,000 "5I-uPA (lane 9, Aand B) wasadded to aliquots (10 Al)
of cell extract from control cultures (A, lanes 10 and 11) or conditioned medium from PMA-
treated cultures (B, lanes 10 and 11) before immunoprecipitation with anti-uPA IgG (lane 10,
A and B) or nonimmune IgG (lane 11, A andB) . The immunoprecipitates were processed for
SDS-PAGE under reducing conditions, and the gels were analyzed by fluorography.
complexes were immunoprecipitated by specific anti-uPA IgG. SDS-PAGE and
autoradiography of the immunoprecipitates (Fig . 2) revealed that, in absence of
PMA (Fig . 2A), anM r 72,000, radioactive complex was specifically immunopre-
cipitated from the U 937 cell extract by anti-uPA IgG (Fig . 2A, lane 3) . We did
not detect newly synthesized low-M, PAI in the corresponding conditioned
medium (lane 7) . In PMA-treated U 937 cells (Fig . 2B), the amount of newly
synthesized low-M, PAI was increased in the cell extract (lane 3) ; additional
bands were also specifically immunoprecipitated : they probably represent deg-
radation products of the M, 72,000 complex. Although U 937 cells have been
shown to secrete the single-chain proenzyme form ofuPA, theamount ofenzyme
produced by these cells is much lower than that of the PAIs (25) and was
therefore not detected in control immunoprecipitates (Fig . 2, lanes 1 and 5) .
Furthermore, PMA induced the synthesis of the high-Mr PAI and its secretion
into the corresponding culture medium (Fig . 2B, lane 7) .
Thus, both low- and high-Mr PAIs are synthesized by U 937 cells . Cell extracts
contain the low-Mr PAL we could not detect any cell-associated high-M, PAI,326
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FIGURE 3 .
￿
The cell-associated low-M, PAI is not accessible to trypsin in intact cells . U 937
cells (106 cells/ml) were resuspended in RPMI + 1 mg/ml BSA (lanes 1-5) or solubilized in
PBS + 0.2% Triton X-100 (lanes 6-10) . The samples were then incubated at 37°C with 5
,ug/ml trypsin . Proteolysis was blocked by the addition of soybean trypsin inhibitor (50 /Ag/ml)
at 0°C after 1 min (lanes 3and 8), 30 min (lanes 4 and 9), or 60 min (lanes 5 and 10) . 1 and
6 : nonincubated samples . 2 and 7 : samples incubated for 90 min at 37°C in the absence of
trypsin . Intact cells were then lysed by addition of 0.2% Triton X-100 ; all samples were
subsequently incubated with '251-uPA and processed for SDS-PAGE andautoradiography .
0 z
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FIGURE 4 .
￿
Kinetics of complex formation of "5I-uPA with the low- and high-M, U 937-
produced PAIs . "'I-uPA (1 .8 nM) wasadded to conditioned media from control (0) or PMA-
treated (0) U 937 cells, which had been diluted with fresh culture medium to contain 1-1 .5
nM free low- or high-M, PAIs . The reaction mixtures were incubated at 37°C; aliquots were
taken at indicated times and processed for SDS-PAGE and autoradiography . The fixed and
stained gel was sliced and radioactivity in the complexes counted in agamma counter .
which thus appears to be preferentially secreted . This pattern was not due to the
coexistence of different subpopulations in the U 937 cell line ; indeed, all of 40
single cell-derived cloned cultures ofU937 cells contained the low-Mr PAI and
secreted mainly the high-Mr form in response to PMA (data not shown) .
To determine whether the low-Mr , cell-associated PAI was exposed at the cell
surface, we incubated U 937 cells in presence of trypsin (Fig . 3) . The low-Mr
PAI present in intact, live cells was totally resistant to proteolysis (lanes 1-5),
whereas it was completely degraded when cells had been solubilized before their
incubation with trypsin (Fig . 3, lanes 6-10) . This indicates that the low-M, PAI
is intracellular .
Kinetics of Complex Formation between "'I-uPA and U 937-produced PAR
￿
The
time course of complex formation between "'I-uPA and the low-Mr PAI was
comparable to that with the high-Mr PAI (Fig . 4) : half of the added .251-uPA was
complexed within the first 2-3 min incubation in U 937-conditioned media ;WOHLWEND ET AL .
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FIGURE 5.
￿
Determination of the M,s of the unreacted PAls by gel filtration . Conditioned
media from control (A) or PMA-treated (B) U 937 cells were analyzed by gel filtration on
Ultrogel ACA 54 . Aliquots of the conditioned media before gel filtration (lane 1, A and B)
and ofthe fractions eluted from thecolumn (lanes 2-12)were incubated with M, 33,000' 2'I-
uPA, andthe sampleswere analyzed by SDS-PAGE andautoradiography .TheACA 54 column
was calibrated before each analysis : the position of elution of the markers is indicated: BSA,
M, 67,000 ; OVA, M, 45,000 ;MYO(myoglobin), M, 18,000 .
these PAIs can thus be classified as fast-acting PAIs . Despite a slight decrease in
the rate ofcomplex formation at 4 °C by comparison with that at 37'C (data not
shown), most of the incubations in the present work were performed at 4°C to
minimize nonspecific proteolysis, particularly when crude cell extracts were
assayed .
On the basis of the data illustrated in Fig . 4, and using the same approach as
Eaton et al . (35) (see Material and Methods), we calculated an associationconstant
(k:,ssa) of8 x 105/M . s for the reaction of both low- and high-MrU 937-produced
PAIs, with M, 33,000 or 55,000 human '251-uPA.
Biochemical Characterization ofU 937-produced PALS.
￿
The comparison of the
M,. of free ' 25IuPA with that of uPA/inhibitor complexes does not provide
information on theMr of the free, unreacted PAIs ; indeed theMr of the PAIs
might be affected by their reaction with uPA, as already observed for other
protease/inhibitor interactions (36) . To determine the M, of the PAIs before
their interaction with uPA, we analyzed the conditioned medium of control and
PMA-treated U 937 cells by gel filtration ; the eluted fractions were incubated
with '251-uPA, and the samples were analyzed by SDS-PAGE and autoradiogra-
phy (Fig . 5) . The low-M, PAI present in conditioned medium of untreated U
937 cells (Fig . 5A) was found in fractions corresponding to an M, of 40,000 .328
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FIGURE 6 .
￿
Glycosylation of the U 937-produced PAIs . (A) Effect oftunicamycin . U 937 cells
(2 x 106 cells/ml) were incubated for 10 h at 37°C in RPMI + 1 mg/ml BSA in absence or in
presence of 10 ng/ml PMAand/or 1 ug/ml tunicamycin, as indicated . Theconditioned media
(lanes 2-5) and cell extracts (lanes 6-9) were then incubated with M, 33,000
1211_UPA (lane
1), and analyzed by SDS-PAGE and autoradiography . (B) Affinity chromatography of the U
937 PANon Con A-Sepharose . Conditioned medium (0 .6 ml)from PMA-treated U 937 cells
was loaded on a Con A-Sepharose column ; the column was loaded and washed extensively
with PBS (lanes 2-7) and eluted with 0.2 M methyl-a-D-mannopyranoside in PBS + 1 mg/ml
BSA (lanes 8-10) . M, 33,000 '2.I-uPAwasadded to aliquots of the conditioned medium before
chromatography (lane 1) or to the eluted fractions (lanes 2-10) . The samples were finally
processed forSDS-PAGE and autoradiography .
The high-M, PAI secreted by PMA-treated U 937 cells (Fig . 5B) had a more
heterogeneous Mr, in agreement with the broadness of the high-Mr complex
band observed after SDS-PAGE and autoradiography; an averageMr of 55,000
was determined for this PMA-induced high-Mr PAL Thus, the additive M rs of
uPA and free PAls are close to that of the complexes. This suggests that the
enzyme/inhibitor complexes are equimolar, and that reaction with uPA does not
result in the cleavage and release of a large polypeptide ; the uncertainties
inherent to the methods of M,- determination used in our studies do not exclude
the possible release ofa small peptide upon enzyme/inhibitor reaction .
As the observed size heterogeneity of the high-Mr PAI may have been the
consequence of differential glycosylation, U 937 cells were treated with PMA in
presence of tunicamycin, an antibiotic that prevents N-linked glycosylation (Fig .
6A). The production of the high-M, PAI by PMA-treated cells (lane 4) was
completely preventedby tunicamycin (lane 5) ; in contrast, the low-MrPAI present
in the culture medium of untreated U 937 cells (Fig . 6A, lane 2) or in cell
extracts of untreated (lane 6) or PMA-treated cells (lane 8) appeared unaffected
by treatment with tunicamycin (Fig . 6A, lanes 3, 7, and 9, respectively) .
This first evidence for glycosylation of the high-M, PAI was confirmed by the
results of affinity chromatography of theconditioned medium from PMA-treated
U 937 cells on ConA-Sepharose (Fig . 6B) : the high-M, PAI was selectively
retained on the column, from which it could be eluted with the appropriate
sugar (lanes 8-10); the low-Mr PAI was recovered in the flow-through of the
column (Fig . 6B, lanes 2-7) .
IEF of conditioned medium from PMA-treated U 937 cells gave different
values of pl for the two PAIs (Table II) . Upon neuraminidase treatment of the
conditioned medium before IEF, the pl of the high-M, PAI was increased to a
value close to that of the low-M,- PAI; the pl of the latter was not significantly
affected by neuraminidase (Table II).WOHLWEND ET AL .
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TABLE II
Values ofpI ObtainedforU 937-produced Low- and High-M,PAIs :
Effect ofNeura-ninidase
The values of pI were calculated from the data obtained upon isoelectric
focusing of the conditioned media from control or PMA-treated U 937
cells .
FIGURE 7 .
￿
Chemical stability of the U 937-produced PAIs . (A) Both PAIs are inactivated by
propanol . Aliquots of conditioned medium from PMA-treated cells were first supplemented
with 0% (lane 1), 10% (lane 2), or 20% (lane 3) 1-propanol, which was then immediately
removedby lyophilization ; the samples were reconstituted to their original volume with water
and incubated with 1251-uPA . Alternatively, an aliquot of the same conditioned medium was
first incubated with ' 251-uPA before treatment with 40% 1-propanol, lyophilization, and
reconstitution with water (lane 4), as described above . The samples were further processed
for SDS-PAGE and autoradiography . (B) ThePAIs are heat sensitive . Aliquots of conditioned
medium from PMA-treated U 937 cells were heated for 15 min at 50°C (lane 1), 60°C (lane
2), or 70°C (lane 3) . The samples were then incubated with 1251-uPA and analyzed by SDS-
PAGE and autoradiography . (C) Both PAIs are acid-labile . Conditioned medium from PMA-
treated U 937 cells was adjusted to pH 3 and neutralized 2 h later before reaction with M,
33,000' 251-uPA (lane 2); lane 1 : untreated conditioned medium . (D)' 2aI-uPA/PAI complexes
are dissociated by ammonium hydroxide. M r 33,000 1251-uPA (lanes 1, 4, 7, and 10) was
incubated with conditionedmedium from control (lanes 2, 5, 8, and11) or PMA-treated (lanes
3, 6, 9, and 12)U 937 cells . Aliquots of these samples were either analyzed directly (lanes 1-
3) or made 1 M in ammonium hydroxide (lanes 4-12) and lyophilized after 30 min of
incubation at 37°C. The sampleswere reconstituted in water, and analyzed directly (lanes 4-
6) or after a second 1-h incubation at 4°C without (lanes 7-9) or with untreated conditioned
medium from PMA-treated cells (lanes 10-12) .
Taken together, these results demonstrate that the secreted, high-Mr, PMA-
induced PAI is indeed glycosylated and carries terminal sialic acid residue(s) ;
under the same experimental conditions, we have not found evidence for
glycosylation of the low-M, PAL
Stability ofU 937-produced PAR
￿
To further study the similarities and differ-
ences between the two PAIs and their possible relationship with other inhibitors,
we tested their relative lability upon exposure to different conditions .
We had previously observed that the low-M, PAI is inactivated in presence of
propanol (25) ; this was also found to be the case for the high-Mr PAI (Fig . 7A).
The inactivation of the PAls was detectable upon treatment with 10% propanol
p1
PAI type Neuraminidase- Untreated treated
Low M, 5.2 5 .2
High M, 4.7 5 .0330
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FIGURE 8 .
￿
Specificity of theU 937-produced PAIs . (A) The PAIs react with both uPA and
tPA . M, 33,000 1251-uPA (5 ng) (lane 1) was added to aliquots of conditioned medium from
PMA-treated U 937 cells preincubated for 30 min at 4°C with 50 ng tPA (lane 3), 17 ng tPA
(lane 4), 5 ng tPA (lane 5), 1 .7 ng tPA (lane 6), 50 ng uPA (lane 7), 17 nguPA (lane 8), 5 ng
uPA (lane 9), or an equal volume of PBS + 1 mg/ml BSA (lane 2) . The samples were further
processed forSDS-PAGE andautoradiography . (B)TheU 937-produced PAIs are preferential
ligands foruPA.M, 55,000 1251-uPA (2 ng)wasadded to 30,uI of 1 :1 dilutions in fresh culture
medium of human serum (lane 1), human plasma (lane 2),U 937-conditioned medium (lane
3), or to 1 :1 mixtures of U 937 conditioned medium and human serum (lane 4) or human
plasma (lane 5) . The samples were incubated for 1 h at 4°C and further processed for SDS-
PAGE and autoradiography .
(lane 2), whereas exposure to up to 40% propanol did not significantly affect the
preformed complex (lane 4) . Both low- and high-M,. PAIs were similarly inacti-
vated upon incubation at elevated temperature (Fig . 7B) : the formation of
complexes with '251-uPA was partially affected after treatment of conditioned
medium at 60°C (Fig . 7B, lane 2), and completely prevented at 70°C (lane 3) .
Pretreatment of the PAIs at pH 3 (Fig . 7 C) completely prevented their subse-
quent reaction with "'I-uPA (lane 2), whereas the preformed 1251-uPA/PAI
complexes were stable under these conditions (data not shown) . Ammonium
hydroxide (Fig . 7D) caused an almost complete dissociation of preformed en-
zyme/inhibitor complexes (lanes 5 and 6) . Dissociation of the complexes resulted
in the recovery of active enzyme, but not offunctional PAL Indeed, reincubation
of the treated sample (after removal of ammonium hydroxide by lyophilization)
allowed the formation of some high-Mr complexes, presumably by reaction of
dissociateduPA with remaining native PAI (Fig. 7D, lanes 8and9) ; upon further
addition of untreated U 937 conditioned medium (lanes 10-12), all the ammo-
nium hydroxide-dissociated radiolabeled enzyme was again recovered in high-
M,. complexes .
These results are compatible with the model proposed for the reaction of
proteases with inhibitors of the serpin family (32) : upon enzyme/inhibitor reac-
tion, there is an irreversible alteration (presumably a cleavage) of the inhibitor,
and the formation of an ester bond between the enzyme and the modified
inhibitor . This ester bond is cleaved in presence of ammonium hydroxide, with
release of active enzyme and inactivated inhibitor .
Since both low- and high-M,. PAIs were similarly affected by the different
experimental conditions, they may be structurally related and their mode of
action may be identical .
Specificity of PAIs Produced by U 937 Cells.
￿
To investigate the interaction of
the PAIs with other proteases, we used two different approaches . We analyzed
their reaction with tPA by competition studies (Fig . 8A) : preincubation of theUWOHLWEND ET AL .
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FIGURE 9 .
￿
Comparison between theU 937-produced elastase ligand and the PAls . (A) The
elastase ligand present in U 937 cells does not react with uPA . U 937 cells (2 X 10 7 cells/ml)
were solubilized in PBS + 0.5% NP-40 . '251-elastase (2 ng) (lane 1) was then added to aliquots
(30 wl) of the cell extract preincubated for20 min at 37°C with 20 ng unlabeled elastase (lane
3), 20 ng unlabeled uPA (lane 4) or an equal volume of PBS + 1 mg/ml BSA (lane 2) . The
samples were further incubated for 20 min at 37°C and analyzed by SDS-PAGE and autora-
diography . (B) The PAIs and the elastase ligand produced by U 937 cells are antigenically
different . '251-elastase (lanes 1-3) or M, 33,000'251-uPA (lanes 4-6) were added to the U 937
cell extract (prepared as described in A) ; after 20 min at 37 °C, aliquots of the samples were
analyzed directly (lanes 1 and 4) or immunoprecipitated with anti-placental PAI-2 IgG (lanes
2and 5) or nonimmune IgG (lanes 3and 6) . Immunoprecipitation supernatants (lanes 2, 3, 5,
and 6) were further processed for SDS-PAGE and autoradiography .
937 PAIs with excess unlabeled tPA (lanes 3-6) or uPA (lanes 7-9) completely
prevented the formation of complexes with
1251_UPA . In view of the very
restricted specificity of tPA, which rendersa nonspecific degradation of the PAIs
by the added enzyme most unlikely, this result strongly suggests that tPA reacts
with the PAIs produced by U 937 cells .
Alternatively, we tested for formation of complexes with radioiodinated en-
zymes .
I 25I-labeled plasmin, thrombin, plasma kallikrein, and coagulation factor
XIIf, failed to form SDS-resistant complexes when added to the U 937-condi-
tioned medium, although they did react with their respective ligands in the same
experimental conditions (data not shown) .
Incubation of I25I-elastase (Fig . 9A) with NP-40-solubilizedU937 cells resulted
in the formation of an SDS-resistant enzyme/ligand complex (lane 2) ; however,
the formation of this complex was not prevented by preincubation with an excess
of unlabeled uPA (lane 4), whereas it was completely abolished upon preincu-
bation with the same molar excess of unlabeled elastase (Fig . 9A, lane 3) . Similar
results were obtained with I25I-trypsin (data not shown) . In addition, these ligands
were not modulated by culturing the cells in presence of PMA. Furthermore,
the complexes formed with I25I-elastase were not immunoprecipitated by an
antibody raised against the PAI-2 present in placenta (Fig . 9B, lane 2), whereas
1251-uPA/PAI complexes were immunoprecipitated by this antibody (lane 5; see
also Fig . 10) . Thus, the ligands for trypsin and elastase present in U 937 cultures
are clearly different from the PAIs we have characterized . They probably
correspond to a,-proteinase inhibitor, which is expressed in human mono-
cytes/macrophages and in U 937 cells (37), and/or to the fast-acting elastase
inhibitor recently described in these cells by Remold-O'Donnell (38) .
In conclusion, the low- and high-M U 937-produced PAIs are different from
the major plasma protease inhibitors and from protease nexin, which also reacts
with thrombin and plasmin . In view of their restricted specificity, they can be33 2
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FIGURE 111 .
￿
Immunological characterization of theU 937-produced PAIs : crossantigenicity
with PAI-2 from human placenta . M, 33,000 '251-uPA (1 .5 leg/ml) (lane 1) was added to
conditioned medium from PMA-treated U 937 cells (lane 2) ; after I hat 4°C, aliquots of the
sample were immunoprecipitated with anti-uPA IgG (lanes 3and 7), anti-placental PAI-2 IgG
(lanes 4and 8), antiserum to the endothelial PAI-1 (lanes 5 and 9), or nonimmune IgG (lanes
6and 10) .Thesupernatants (lanes3-6) andthe immunoprecipitates (lanes 7-10) were analyzed
by SDS-PAGE and the gel wasprocessed for autoradiography .
referred to as PA-specific inhibitors . Since both PAIs follow the same specificity
pattern, they are, at least functionally, closely related .
To further characterize these PAIs, we compared the relative affinities for
uPA of the low-Mr U 937 PAI and the human plasma or serum antiproteases
(Fig . 8B) . When 55,000 Mr 1251-uPA was incubated solely with serum (Fig . 8B,
lane 1) or plasma (lane 2), several complexes were observed ; these have been
previously identified as complexes of the enzyme with a2-macroglobulin and
antithrombin III (16) . In contrast, if U 937-conditioned medium (lane 3) was
mixed with serum (lane 4) or plasma (lane 5), added 1251-uPA was almost
completely complexed to the U 937 PAI, as evidenced by the presence of aM r
94,000 complex . These results indicate that theU 937-produced PAIs could be
preferential ligands for uPA under physiological conditions in vivo .
U937-produced PAIs AreAntigenically Related to Each Other and toPAI-2Isolated
from Human Placenta . The properties of the U 937-produced PAIs are remi-
niscent of those of the PAI-2 first identified in human placenta (4, 5, 39) . In
addition, we have indirect evidence that these PAIs are different from the PAI-
1 produced by endothelial cells (12) and also present in human platelets (14) and
in serum (21) ; indeed, this PAI is unusually stable to SDS, acid, and to heating
at 100'C (12) . To confirm this, we immunoprecipitated the complexes formed
by addition of 1251-uPA to conditioned medium of PMA-treatedU 937 cells (Fig .
10), using antibodies directed againsthumanuPA (lanes 3and 7), placental PAI-
2 (lanes 4 and 8), endothelial PAI-1 (lanes 5 and 9), or nonimmune IgG (lanes 6
and 10) . The major complexes corresponding to the low- and high-Mr PAIs were
specifically immunoprecipitated by antibodies directed to the placental PAI-2
(lane 8) ; in addition, a minor complex of intermediateMr , that we had failed to
resolve before immunoprecipitation because it was masked by the high-Mr
complex, was immunoprecipitated by antibodies directed to the endothelial PAI-
1 (Fig . 10, lane 9) .
Thus, the low- and high-M r PAIs that we have characterized are immunologi-WOHLWEND ET AL .
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FIGURE 11 .
￿
Production of PAIs by human peripheral blood monocytes/macrophages . (A)
Human peripheral blood monocytes/macrophages also secrete the high-M, PAL M, 33,000
"'I-uPA (2 ng) was added to 10 gl of conditioned medium from U 937 cells (lanes 1 and 2)
or from human monocytes (lanes 3 and 4) that had been previously cultured for 24 h in
absence (lanes 1 and 3) or in presence (lanes 2 and 4) of 30 ng/ml PMA. After I h at 4°C, the
sampleswere analyzed by SDS-PAGE and autoradiography . (B) These PAIs are antigenically
related to the placental PAI-2. Monocyte-conditioned medium was analyzed exactly as de-
scribed in Fig . 10 . The supernatants (lanes 3-6) and the pellets (lanes 7-10) of immunoprecip-
itations with anti-uPA IgG (lanes 3and 7), anti-placental PAI-2 IgG (lanes 4 and 8), antiserum
to the endothelial PAI-1 (lanes 5and 9), or nonimmuneIgG (lanes6and 10)were subsequently
processed for SDS-PAGE andautoradiography.
cally related to a functionally similar protein (PAI-2) purified from human
placenta ; this also indicates that they are related to each other, and hence that
they may represent postsynthetic modifications of a same precursor. The pres-
ence oflow levels of PAI-1 in conditioned medium ofU 937 cultures indicates
that a presumably homogeneous cell population can produce different PAIs .
Human Monocytes/Macrophages Isolated from Peripheral Blood Secrete the High-
M, Form of PAL We had previously shown (25) that primary cultures of
peripheral blood monocytes/macrophages released the low-M, PAL Subsequent
analysis of other conditioned media revealed that primary cultures can release
the high-M, PAI, in response to PMA (Fig .
￿
11 A), and also under resting
conditions (data not shown) . The variable ratio of low- to high-M, PAls observed
among different primarycultures presumably reflects : (a)thedifferential viability
of the cells in different cultures ; since the low-M, PAI is abundant in cell extracts
(see Table 1), lysis of a small fraction of the cells will result in accumulation of
this PAI in the conditioned medium ; (b) the status of activation of the cells ;
indeed, in cultures of mouse peritoneal macrophages, the production of both
low- and high-M, PAIs varies as a function of the inflammatory state of the
animal .'
PAis Secreted by Human Monocytes/Macrophages Are Antigenically Related to
Placenta-derived PAI-2. The antigenic relationship of the PAls produced by
human peripheral blood monocytes/macrophages with those from human pla-
centa or endothelial cells was investigated by immunoprecipitation . The low-M.
complex formed upon incubation of monocytes/macrophages-conditioned me-
dium with 1251_UPA was analyzed using specific antibodies directed to the placen-
tal PAI-2 and the endothelial PAI-1 (Fig . 11 B) . We occasionally observed a
splitting of the low-M, PAI/uPA complex into a closely spaced doublet after
2 Wohlwend,A., D. Belin, and J.-D . Vassalli . Plasminogen activator-specific inhibitors in mouse
macrophages : in vivo and in vitro modulation of their synthesis and secretion . Manuscript submitted
for publication .334
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SDS-PAGE ofboiled samples; this may have resulted from a proteolytic cleavage
ofthe low-M, PAI upon its interaction with uPA, as suggested by Kruithof et al.
(40) and Nielsen et al. (41). Like the PAIs produced by the U 937 cell line, the
low-MT PAI secreted by peripheral blood monocytes/macrophages was antigeni-
cally related to PAI-2 (Fig. 11 B, lane 8). Similar results were obtained with
conditioned medium containing the high-M,- PAI (data not shown). In contrast
to what was observed for the U 937 cell line, we did not detect a complex related
to the PAI-1 (lane 9) in cultures of human monocytes/macrophages.
Discussion
The results of the present work provide conclusive evidence for the synthesis
and secretion ofPAIs by cultured human monocytes/macrophages. In particular,
we have shown that these cells produce two structurally distinct PAIs that differ
in their cellular localization, although they are immunologically and functionally
indistinguishable. Their lack of reactivity toward a number of other serine
proteases besides uPA and tPA suggests that they may be PA-specific. In view of
their high rate ofassociation with uPA, they could be effective PAIs in vivo; this
contention is supported by the observation that they are preferential ligands of
UPA, when added to human plasma or serum, at a concentration several orders
of magnitude lower than that of the major circulating antiproteases. Together,
these results point to a possible role of these PAIs in limiting PA-catalyzed
extracellular proteolysis, in particular in the context of inflammatory reactions
involving mononuclear phagocytes.
The production of PAIs by human or murine monocytes/macrophages has
been reported previously (22-28, 42). Our results confirm in particular those of
Chapman and Stone (26) and of Kopitar et al. (28); indeed, the immunological
crossreactivity and biochemical similarity of the PAIs from mononuclear phago-
cytes with the previously characterized placenta-derived PAI-2 have been veri-
fied. In addition, we demonstrate here thesynthesisofthese PAIsby the cultured
cells, and its regulation by PMA, a hormonal-like modulator. Furthermore, our
study has revealed a hitherto unrecognized feature of this antiprotease system:
the existence of two distinct, but related, forms of PAL This observation was
greatly facilitated by the analytical method we used, i.e., the detection of stable
complexes between radiolabeled enzyme and inhibitors by SDS-PAGE and au-
toradiography (7). The presence of complexes of different M,s provided a first
evidence forthe existence ofdistinct PAIs. Further studiesrevealed the following
characteristics for these two PAIs: An Mr 40,000, pI 5.2, presumably nonglyco-
sylated PAI was found in cellextracts under all conditions tested. A small fraction
of the total amount of this low-M, PAI was also found in culture supernatants.
Although synthesized by the cells during the culture, its release was not affected
by inhibitors of macromolecular synthesis; this release may thus correspond to
secretion of preformed stored PAI, or to leakage from damaged cells. The
resistance to proteolysis of this PAI when intact cells were incubated with trypsin
indicates that it is intracellular, and not cell surface-associated; subcellular
fractionation will be required to determine its precise localization. A PAI of
higher and more heterogeneous M,, ranging from 50,000 to 65,000, was found
exclusively in the conditioned medium. This PAI had a pI of 4.7, and wasWOHLWEND ET AL.
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glycosylated with terminal sialic acid residue(s). Its synthesis and secretion were
markedly stimulated when cellswereculturedin presence of PMA. Nofunctional
difference was found between these two PAIs; in particular, their respective
lability, enzymatic specificity and immunological reactivity were identical. We
conclude that they probably represent two forms of the same PAI, which are
related to PAI-2.
The characteristics of the PAI purified from placental tissue suggest that it is
comparable to the low-M,, predominantly intracellular PAI from mono-
cytes/macrophages. Thus, cell and tissue extracts may in general contain mostly
the low-M, form of the protein, whereas the high-M, form would be found
exclusively in extracellular compartments. This model is supportedby the recent
identification ofanM, 70,000 PAI, immunologicallyrelated to thePAI-2 protein,
in human pregnancy plasma (20). Furthermore, we have observed that a number
ofcell lines unrelated to mononuclear phagocytes also contain and secrete PAIs
that react with antibodies to PAI-2 (43); as shown here for monocytes, a low-Mr
form was consistently found in cell lysates, whereas conditioned media contained
predominantly a high-M,, form (A. Estreicher, manuscript in preparation).
Thechromatographic andelectrophoretic differences between thesetwo forms
of PAls can probably be accounted for by differences in glycosylation. Indeed,
after removal of sialic acid residues by neuraminidase, the size of the high-M,
PAI is only slightly above that ofthe low-M, species (data not shown), and their
pIs are also very close. Hence, the PMA-induced secretion of the high-M, form
may be due to post-translational modification (i.e., glycosylation) of newly-
synthesized low-M, PAI; it could also result from saturation ofa postglycosylation
modification process, which generates the preferentially intracellular low-M,
species by removing the carbohydrate side chains from the high-M,, form.
Alternatively, PMA may enhance the synthesis of a distinct PAI, carrying
appropriate determinants for glycosylation and secretion; this could result from
transcription of a different gene for the high-M, PAI, or from alternate splicing
of a common precursor mRNA. These issues can only be resolved by determi-
nation ofthe structure ofthe two PAIs. A first step in this direction is the recent
purification and partial sequencing of the low-M,, U 937-produced PAI, which
belongs to the antithrombin III family of antiproteases (40); antibodies raised
against the purified protein also react with the high-M, PAL
It is well established that the plasminogen-dependent proteolytic activity of
mononuclear phagocytes varies considerably as a function of the inflammatory
status of the animal (2); similarly, PA production by cultured monocytes/
macrophages, as measured by overall proteolytic activity, can be modulated by a
variety of hormones and mediators (30, 44, 45). The PA activity of mature
mononuclear phagocytes is entirely due to uPA, and allthe observed modulations
are associated with changes in the rate oftranscription of the uPA gene and in
the level ofuPA mRNA (46).s However, it appears that the production of PAIs
is also a phenotypic property of monocytes/macrophages that can be modulated:
endotoxin (23) and muramyl dipeptide (24) have been shown to increase PAI
levels in macrophage and monocyte cultures, and our results show the modulation
s Collart, M. A., D. Belin, J.-D. Vassalli, and P. Vassalli. cfos expression in differentiated macro-
phages: earlychangesduring modulation offunctional activity. Manuscript submittedforpublication.336
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of synthesis and secretion of PAIs in response to PMA. Using a similar approach,
we have studied PAI production by cultured mouse macrophages .' We have
identified and characterized two PAIs synthesized by these cells, which are
biochemically, functionally and antigenically similar to the human proteins
described here. Their production varies dramatically as a function of the inflam-
matory status of the animal, and can also be hormonally modulated in vitro; the
balance between uPA and its inhibitors is likely to be central to the control of
proteolysis in inflammation .
Summary
Human monocytes/macrophages produce plasminogen activator-specific in-
hibitors (PAIs) that form covalent complexes with urokinase-type plasminogen
activator (uPA). We have characterized two functionally and antigenically related
forms of PAIs produced by resting and phorbol myristate acetate (PMA)-treated
U 937 cells: an M,. 40,000 form, presumably nonglycosylated, with a pI of 5.2,
that is constitutively synthetized by these cells and that remains predominantly
intracellular; a PMA-induced form of heterogeneous Mr (50,000-65,000) with a
pI of 4.7, that is preferentially secreted; this PAI is glycosylated with terminal
sialic acid residue(s).
Biosynthetic labeling experiments demonstrated that both PAN are synthetized
by U 937 cells. They are inactivated upon treatment with propanol, heat, and
acid ; the covalent and equimolar complexes formed between these PAIs and
1251-
uPA are dissociated by ammonium hydroxide, suggesting that the PAIs are
linked to uPA via an ester bond. Human peripheral blood monocytes/
macrophages also produce the two forms of PAL These PAIs are clearly different
from the main plasma protease inhibitors and they are both antigenically related
to the PAI-2 characterized in human placenta.
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